Tobam Nektar Therapeutics Transaction History

Tobam

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$15.87 - $23.12 $9.26 Million - $13.5 Million	-583,414 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $538,515 - $1.16 Million	31,846 Added 5.77%	583,414 $10.6 Million
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $2.76 Million - $3.23 Million	-88,979 Reduced 13.89%	551,568 $19.6 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $955,800 - $1.4 Million	-30,266 Reduced 4.51%	640,547 $21.5 Million
Q4 2018 Feb 11, 2019	BUY	$30.43 - $56.65 $7.32 Million - $13.6 Million	240,434 Added 55.87%	670,813 $22.1 Million
Q3 2018 Nov 08, 2018	SELL	$46.46 - $68.49 $2.6 Million - $3.83 Million	-55,957 Reduced 11.51%	430,379 $26.2 Million
Q2 2018 Aug 03, 2018	BUY	$46.25 - $104.45 $22.5 Million - $50.8 Million	486,336 New	486,336 $23.7 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

Stay updated on Tobam with notifications on news.